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Botanical Dietary Supplement Safety:
A brief historical overview


Plants have been a source of drugs since time immemorial.



In the U.S. plants and plant extracts were a mainstay in medicine until
after WWII. At that point, drugs transitioned from multi-ingredient plantbased products to synthetic, single-ingredient API.





By the late 1970’s, most colleges of pharmacy removed “pharmacogosy”
courses (the study of plant-derived medicines) from their curricula.

In 1994, passage of DSHEA and the influx of botanical dietary
supplements caught most health-care professionals unaware of how to
deal with these new pharmacological entities.

Lessons learned from 25 years of
botanical dietary supplement research
1.

BDS are complex phytochemical mixtures that beget complex research problems and
solutions (e.g, “Proprietary blends”).

2.

Products must be independently verified for phytochemical content
(e.g., “Content vs. label claim”).

3.

Contamination and adulteration plague many BDS categories.

4.

Human clinical pharmacokinetic parameters (e.g., clearance, bioavailability, half-life, etc.)
for most unique phytochemicals are unknown (exceptions: caffeine, ephedrine alkaloids).

5.

BDS can interact with conventional medications, although only a few appear to be
clinically relevant.

6.

BDS dosage form performance (e.g., disintegration and dissolution) is largely unknown and
can adversely affect clinical study outcomes.

7.

Significant disconnects exist between in vitro HDI predictions and in vivo realities.

8.

Novel BDS dosage forms may enhance efficacy and/or toxicity.

9.

Despite 25 years of use, health-care professionals are still largely ignorant of the positive
and negative aspects of BDS.

Botanical Dietary Supplement (BDS) Safety:
Overview


Introduction.



Historical overview with examples (”The Ephedra Wars”)



Basic BDS safety concerns: Most single ingredient BDS are safe



Single-ingredient vs. “proprietary blends”



Herb-induced liver injury



Contamination and adulteration



Herb-drug interactions: St. John’s wort and MDP-containing phytochemicals



Dosage form performance and its influence on BDS safety



Predicting BDS safety: methodologies and their utility



A discomfiting legacy: health care professionals still know little about BDS

Botanical Dietary Supplements (BDS):
Items for Discussion (cont.)

• A lot has changed in 25 years: Global supply chain, Global
marketing platforms (Amazon), novel products, etc. How do we
get the minor players in the industry to become more concerned
about product safety?

• Should there be another tier/category of BDS products that have
demonstrated adequate quality and safety? Can this “safety
assurance” impart market exclusivity for “health safety” claims.

• After 25 years, is there now a need for BDS CROs that can

conduct the proper clinical “safety” studies for products aiming
for this upper-tier category?

Effect of SJW on CYP3A4 Phenotype

Gurley et al., Clin. Pharmacol. Ther. 2002; 72:276-287
Gurley et al., Drugs & Aging 2006; 46:201-213

Effect of SJW on Cyclosporine Trough Concentrations

GW Barone, BJ Gurley, et al. Ann. Pharmacother. 2000:34:1013

BDS can interact with Rx
What makes St. John’s wort so problematic?

• Mechanism:
Induction of CYPs (e.g., CYP3A4, 2C9, 2E1) and efflux transporters
(e.g., ABCB1, ABCG2)
Binds to hPXR to induce CYP and ABC gene expression
• Responsible phytochemicals: Hyperforin, adhyperforin
Most potent hPXR ligand yet discovered!
(Ki ≈ 25nM)
More potent than rifampin!

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacokinetic HDI)
Broken circle = methylenedioxyphenyl (MDP) moiety

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacokinetic HDI)
Botanicals with phytochemicals containing MDPs
that produce clinically relevant HDI are:
Plant species

MDP-containing phytochemical

Berberis spp.

Berberine

Coptis spp.

Berberine

Hydrastis canadensis

Berberine, hydrastine

Piper longum

Piperine, piperamides

Piper nigrum

Piperine, piperamides

Schisandra spp.

Gomisins, schisantherins, schizandrols

Gurley et al., Planta Med. 2012;78:1490-1514

Bioavailability of most phytochemicals is poor
Is poor dosage form performance a factor?
• cGMPs do not require dissolution & disintegration testing.

• USP dissolution standards not established for all botanical monographs.
• Few clinical studies of botanicals assess dosage form performance.
• Dosage form performance = disintegration and dissolution
‒ Poor disintegration & dissolution can adversely affect bioavailability.
– Dissolution often a function of physicochemical properties
(e.g., molecular wt., aqueous solubility, permeability, etc.)

Bioavailability of most phytochemicals is poor
Is poor dosage form performance a factor?

Goldenseal extract
(capsules)
Water solubility of
hydrastine & berberine
~20 mg/mL

Kava extract
(capsules)

Kava extract
(liquid gel caps with lecithin)

Water solubility of
methysticin & dihydromethysticin
< 0.8 mg/mL

Roe et al. Reg. Toxicol. Pharmacol.. 76:1-6 (2016)

Emerging technologies for improving phytochemical bioavailability
• Recognizing that many “active” phytochemicals have poor aqueous
solubility and/or permeability, new formulation technologies have been
implemented to improve dissolution and bioavailability.
• Liposomes
• Phytosomes (complexes of polyphenols and phosphatidylcholine)
• Self-emulsifying drug delivery systems (SEDDS)
• Nanoparticles
• Phytochemical inhibitors of xenobiotic metabolism
(e.g., piperine)
• None of these new botanical formulations have been evaluated for their
drug interaction potential in humans.

Emerging technologies for improving phytochemical bioavailability

A

Liposomal formulation greatly improves
dissolution of milk thistle silymarin (A)
and its oral bioavailability (B).

B

Yan-yu et al. Int. J. Pharm. 319:162-168 (2006)
El-Samaligy et al. Int. J. Pharm. 319:162-168 (2006)

BDS Safety:
General considerations


Today, BDS are for sale in pharmacies, health food stores,
grocery stores, and various other retail outlets including the
internet.



BDS are oral dosage forms (e.g., tablets, capsules, liquids, etc.)
containing various types of botanical extracts
(i.e., aqueous, non-aqueous, and mixed extracts).



Two major categories of BDS:


Single-ingredient products (e.g., Ginkgo biloba, saw palmetto, echinacea, St.
John’s wort, etc.)



Multi-ingredient products (“Proprietary Blends”)

(e.g., weight-loss aids, exercise performance enhancers [“pre-workout supplements”],
sexual performance enhancers, etc.)

BDS Safety:
Popularity of BDS
l

l

l

In 1994, ~4000 products were on the U.S. market and annual
sales were <$100M
In 2019, roughly 75,000 dietary supplement products are on the
market today, accounting for >$30B in annual sales. BDS sales
are ~$10B annually. (Things have certainly changed in 25 years!)
Approx. 60-70% of U.S. population take some form of DS
(i.e., vitamins, minerals & botanicals).

BDS Safety:
With popularity comes safety concerns

l

l

l

Surveys indicate that 20-30% of Rx drug users in the U.S. take
botanical supplements concomitantly.
Less than 40% of patients reveal use of herbal dietary
supplements to health care professionals
Herb-drug interactions pose significant safety risks to
consumers.

BDS Safety:
DSHEA and BDS safety
l

For the last 25 years, safety requirements for botanicals have
been linked to intended their use (e.g., food, dietary supplement,
cosmetic, botanical drug)

l

DSHEA provides the regulatory safety framework for dietary
supplements, but growth and innovation in the supplement
market may have challenged a law developed 25 years ago.
“I’m concerned that changes in the supplement market may have outpaced the evolution
of our own policies and our capacity to manage emerging risks.” - Gottlieb 2019.

BDS Safety:
Some questions to ponder
l

l

l

Does DSHEA in its current form still provide a
reasonable approach to monitoring BDS safety?
If so, is there a better way to utilize the existing
regulatory framework of DSHEA?
If not, how best can we go forward with
modifications to DSHEA with regard to improving
BDS safety?

BDS Safety:
Events impacting BDS safety over the last 25 years
1994
1995
1997
2000

2002
2004
2006
2007
2008
2010
2013

Legislative Acts
FDA Rulings
NIH-related Actions
Safety-related Issues

Dietary Supplement Health & Education Act passed
Adverse events linked to ephedra use first reported
Office of Dietary Supplements (ODS) at NIH begins operations
FDA issues proposed ruling on adulteration of ephedra supplements
Organ transplant rejection linked to interaction between SJW and cyclosporine;
First jury trial involving an ephedra-related injury (verdict in favor of plaintiff)
NCCAM funds first Botanical Research Centers
Research into herb-drug interactions begins in earnest
FDA rules ephedra supplements are adulterated and removes them from US market;
Adverse events related to ephedra-free supplements first reported
FDA establishes rules for adverse event reporting for dietary supplements.
Dietary Supplement & Nonprescription Drug Consumer Protection Act passed
FDA issues final ruling on dietary supplement GMPs
Rash of reports finding BDS adulterated with undeclared drugs and anabolic
steroids; FDA removes (and continues to remove) adulterated BDS from US market
Food Safety Modernization Act passed enhancing FDA recall authority for food & BDS
Spate of liver injuries linked to use of OxyELITE Pro (OEP); FDA deems OEP
adulterated and removes it from the US market
Gurley et al, Clin. Pharmacol. Ther. 2018;104:470-483

BDS Safety:
Events impacting BDS safety over the last 25 years

Legislative Acts
FDA Rulings
NIH-related Actions
Safety-related Issues

2014 Designer Steroid Control Act passed expanding list of anabolic steroids regulated by
Drug Enforcement Agency
2015 NCCIH (formerly NCCAM) establishes Center of Excellence for Natural Product Drug
Interaction Research;
Using inappropriate testing methodology (DNA fingerprinting of finished BDS
products), New York Attorney General erroneously targets major retailers for selling
fraudulent BDS and demands products be removed from shelves.
2016 Department of Justice files criminal charges against the maker of OxyELITE Pro (USP
Labs)

2018 FDA bans the sale of BDS containing highly concentrated or pure caffeine
2019 FDA Director expresses desire that DSHEA be revised to improve BDS safety oversight;
USP Labs pleads guilty to criminal charges related to OxyELITE Pro

Gurley et al, Clin. Pharmacol. Ther. 2018;104:470-483

Botanical Dietary Supplements (BDS):
Historical overview regarding BDS safety
l

Several categories of BDS have posed significant safety
concerns over the past 25 years.
l

Weight-loss / Exercise performance enhancement BDS
l
l
l

l
l
l

Ephedra-containing BDS (Who in this room is not a veteran of the Ephedra Wars?)
Ephedra-free BDS (Adverse events similar to Ephedra-containing BDS)
BDS linked to liver injury (Lipokinetix, OxyELITE Pro, others)

St. John’s wort (renders most medications ineffective)
MDP-containing BDS (Berberis, Coptis, Piper nigrum, Schisandra, others)
Adulterated/contaminated BDS
l
l
l
l

Pyrrolizidine alkaloids
Aristolochic acid
Prescription medications (Weight-loss, Pre-workout, Sex enhancement BDS)
Heavy metals

Botanical Dietary Supplements (BDS):
Historical overview: Ephedra-containing BDS

Botanical Dietary Supplements (BDS):
Historical overview: Ephedra-free BDS

Botanical Dietary Supplements (BDS):
Historical overview: Ephedra-free BDS
l

l

l

l

l

In 2013, a host of serious liver injuries, some requiring liver
transplantation, and several deaths were linked to the use of OxyELITE Pro (OEP).
Marketed as an exercise performance enhancer, its ingredients had never been
formulated together, and one (aegeline) had never been administered to humans.
Product contained no botanical extracts, only synthetic compounds (i.e., caffeine,
aegeline, higenamine, yohimbine).
FDA removed the product from the market in 2014, sued the manufacturer (USP Labs) in
2016, defendants pled guilty in 2019.

Recent studies in mice demonstrated OEP hepatotoxicity at doses equivalent to that
recommended in humans. OEP at doses 3X recommended dose were often deadly.
(Narrow safety margin!)
Miousse IR, et al. Food Chem. Toxicol.109:194-209 (2017)
Skinner CM, et al. Food Chem. Toxicol.122:21-32 (2018)

Botanical Dietary Supplements (BDS):
Single ingredient vs Proprietary Blends
l

l

l

l

Botanical extracts are complex mixtures of numerous phytochemicals.
“Proprietary blends” are BDS containing multiple botanical extracts,
many of which have never been combined before as part of the diet.
BDS formulations utilize concentrated plant extracts. Phytochemical
exposure is much greater as an extract than consuming the plant in its
natural state.
Most phytochemicals have not been characterized for pharmacological
activity, never mind combinations of multiple phytochemicals from
multiple extracts.

Botanical Dietary Supplements (BDS):
Single ingredient vs Proprietary Blends
A partial listing of phytochemicals present in St. John’s wort
Naphthodianthrones

hypericin
pseudohypericin
protohypericin
protopseudohypericin
cyclopseudohypericin
Xanthones

1,3,6,7-tetrahydroxyxanthone
kielcorin
Phloroglucinol derivatives

hyperforin
hydroperoxycadiforin
adhyperforin

Flavonoids

luteolin
13, II8-biapigenin
amentoflavone
hyperin
catechin derivatives
epicatechin derivatives
quercetin
kaempferol
hyperoside
quercitrin
isoquercitrin
rutin
myricetin

Essential Oils

methyl-2-octane
pinenes
terpineol
geraniol
limonene
caryophyllene
humulene

Botanical Dietary Supplements (BDS):
Single ingredient vs Proprietary Blends
l

l

l

Ephedra-containing BDS remain perfect illustrations of safety
concerns inherent in “proprietary blends.”
Placing the burden of safety on the FDA or independent
researchers, and not the manufacturer, is simply illogical from
a safety perspective regarding complex phytochemical
mixtures.
Many other variables impact the pharmacology of proprietary
blends: age, genetics, exercise, prescription and/or nonprescription
medications, others.

Botanical Dietary Supplements (BDS):
Contamination and Adulteration
l

l
l

l

Current Good Manufacturing Practices (cGMPs), have
significantly impacted the quality and safety of BDS.

Unfortunately cGMPs were not fully implemented until 2008.
While most DS manufacturers adhere to cGMPs, not all are fully
compliant.
As a result, certain categories of BDS (e.g., weight-loss BDS,
exercise performance enhancement BDS, sexual performance
enhancement BDS) are frequently adulterated and/or
contaminated.

Botanical Dietary Supplements (BDS):
Contamination and Adulteration

l

Rx adulterants: anabolic steroids, barbiturates, benzodiazepines,
corticosteriods, diuretics, NSAIDs, PDE-5 inhibitors, phenytoin, rimonabant,
sibutramine, theophylline, thyroid hormones, many others.

l

Economic adulterants: plant extracts, essential oils, etc. that are not
representative of the label claim but are easier and cheaper to acquire.

l

Contaminants: Bacteria, fungi, pesticides, heavy metals (Hg, Pb, Cd, As)

Botanical Dietary Supplements (BDS):
Herb-induced liver injury
l

Refer to comments of the previous ICSB panel
regarding this topic.

Botanical Dietary Supplements (BDS):
Herb-drug Interactions

l

l

l

20-30% of Rx drug users in the U.S. take botanical supplements
concomitantly.
Less than 40% of patients reveal use of herbal dietary
supplements to health care professionals
Herb-drug interactions pose significant safety risks to
consumers.

Botanical Dietary Supplements (BDS):
Herb-drug Interactions
l

l

Herb-drug interactions (HDI) can be categorized as either pharmacodynamic
or pharmacokinetic.

Pharmacodynamic HDI involve phytochemicals whose pharmacological
activity can either negate or enhance the activity of a prescription
medication.
(e.g. Ephedra-free BDS containing high quantities of caffeine can increase blood pressure and
thus can negate the effects of many antihypertensive drugs.)

l

Pharmacokinetic HDI involve phytochemicals that can either inhibit or induce
the activity of drug metabolizing enzymes (e.g. CYPs, UGTs, sulfatases, etc.) and/or
transporters (e.g. P-glycoprotein, OATP, OCT, etc.).

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacodynamic HDI)
BDS noted for producing clinically relevant
pharmacodynamic HDI include:
BDS

Ephedracontaining
BDS

Ephedrafree BDS

Liquorice
Root*
(G. glabra)

HDI Risk

HDI Mechanism

Phytochemicals

High

Pharmacodynamic
Cardiovascular and
CNS stimulant
effects

Ephedrine
alkaloids, caffeine,
other natural
stimulants

Increased BP, HR;
Avoid
increased risk of
concurrent use
with Rx
adverse
cardiovascular & antihypertensive
CNS health effects s and stimulants

High

Pharmacodynamic
Cardiovascular and
CNS stimulant
effects

Caffeine and other
natural stimulants
(e.g., yohimbine,
synephrine, etc.)

Increased BP, HR;
Avoid
increased risk of
concurrent use
with Rx
adverse
cardiovascular & antihypertensive
CNS health effects s and stimulants

High

Pharmacodynamic
Cardiovascular and
CNS stimulant
effects

Glycyrrhizic acid

Consequences

Increased BP with
prolonged use

* = This risk assessment does not apply to deglycyrrhizinated liquorice root products

Precautions

Avoid
concurrent use
with Rx
antihypertensive
s

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacodynamic HDI)
l

Liquorice root extract

l

Interaction mechanism:
Chronic use leads to sodium retention, potassium depletion due to mineralocorticoid effect of
glycyrrhizic acid and its metabolite (monoglucuronyl-18b-glycyrrhetinic acid) which inhibits
11-b-hydroxysteroid dehydrogenase 2. (11bHS2 converts cortisol to cortisone.)

l

Interactions:
Antihypertensives (diuretics), antiarrhythmics

l

Consequences:
Hypertension, hypokalemia, arrhythmias

Glycyrrhizic acid

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacokinetic HDI)

• St. John’s wort (Hypericum perforatum) is perhaps the most
problematic BDS with regard to pharmacokinetic HDI.

• Indication: Anti-depressive
• Efficacy: Good (product-dependent)
• Drug Interaction Risk: Very High! Renders most drugs
ineffective

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacokinetic HDI)

• SJW HDI Mechanism:
Induction of CYPs (e.g., CYP3A4, 2C9, 2E1) and efflux transporters
(e.g., ABCB1, ABCG2)
Binds to hPXR to induce CYP and ABC gene expression
• Responsible phytochemicals:
Hyperforin, adhyperforin
Most potent hPXR ligand yet discovered!
(Ki ≈ 25nM)
More potent than rifampin!

Botanical Dietary Supplements (BDS):
Herb-drug Interactions (Pharmacokinetic HDI)

l

l

l

Unlike SJW, many phytochemicals containing
methylenedioxyphenyl (MDP) moieties inhibit human CYP
enzymes.
Inhibition of human CYPs by MDP-containing phytochemicals is
“time-dependent” or “mechanism-based.”
This type of enzyme inhibition renders drugs more toxic,
leading to clinically relevant HDI.

Botanical Dietary Supplements (BDS):
Herb-drug Interactions

Echinacea

Black cohosh

Saw palmetto

Ginkgo biloba

• Most popular botanical supplements do not appear to pose a serious
drug interaction risk; however, the vast majority have yet to be studied
in a clinical setting.

• Systemic effects of many botanical DS are minimal due to:
— poor dosage form performance
— extensive pre-systemic metabolism

Botanical Dietary Supplements (BDS):
Dosage Form Performance & BDS Safety

• cGMPs do not require dissolution & disintegration testing.
• USP dissolution standards not established for all botanical monographs.
• Few clinical studies of botanicals assess dosage form performance.
• Dosage form performance = disintegration and dissolution
‒ Poor disintegration & dissolution can adversely affect bioavailability.
‒ Poor dosage form performance reduces efficacy but enhances safety.
– Dissolution often a function of physicochemical properties
(e.g., molecular wt., aqueous solubility, permeability, etc.)

Botanical Dietary Supplements (BDS):
Dosage Form Performance & BDS Safety
Definition:

Process by which a solid substance (drug/phytochemical) dissolves
in a specified aqueous medium. Dissolution rate is amount of drug/phytochemical
substance that goes into solution in a specified time
under standardized conditions of liquid/solid
interface, temperature, and solvent composition.

Dissolution Apparatus:
Basket Apparatus
Paddle Apparatus
Reciprocating Cylinder
Flow-Through Cell

Procedures and tolerances defined only for a limited
number of botanical monographs: Plot percent dissolved vs. time

Botanical Dietary Supplements (BDS):
Dosage Form Performance & BDS Safety

Goldenseal extract
(capsules)
Water solubility of
hydrastine & berberine
~20 mg/mL

Kava extract
(capsules)

Kava extract
(liquid gel caps with lecithin)

Water solubility of
methysticin & dihydromethysticin
< 0.8 mg/mL

Botanical Dietary Supplements (BDS):
Dosage Form Performance & BDS Safety
• Recognizing that many “active” phytochemicals have poor aqueous solubility and/or
permeability, new formulation technologies have been implemented to improve
dissolution and bioavailability. None of these new botanical formulations have been
evaluated for their drug interaction potential in humans.
• Liposomes
• Phytosomes
• Self-emulsifying drug delivery systems (SEDDS)
• Nanoparticles
• Phytochemical inhibitors of xenobiotic metabolism
(e.g., piperine)

Botanical Dietary Supplements (BDS):
Dosage Form Performance & BDS Safety

A

Liposomal formulation greatly
improves dissolution of silymarin (A)
and its oral bioavailability (B).

B

Botanical Dietary Supplements (BDS):
Dosage Form Performance & BDS Safety
• BENEFITS: Improving phytochemical bioavailability through novel
formulation technologies may lead to improved phytochemical efficacy.
• RISKS: With improved bioavailability may come an increased risk of toxicity
and/or herb-drug interactions.
• FUTURE: Few randomized, controlled clinical trials have been conducted
with these new novel formulations. The future of BDS may hinge on the
success of these technologies.

Botanical Dietary Supplements (BDS):
Predicting BDS Safety
l

l

l

At present, most single-ingredient BDS appear to be relatively safe.
A number of factors contribute to the safety of most singleingredient BDS:
l

Extensive pre-systemic metabolism

l

Poor dosage form performance

l

Consumption of BDS with food

l

Quality control issues: “content vs. label claim”

“Proprietary blends,” however, often pose a greater safety risk.

Botanical Dietary Supplements (BDS):
Predicting BDS Safety

l

l

l

At present, adverse event reports, case reports, poison control
center calls, etc., are the principal “predictors” of BDS safety.
These methodologies, while infrequently submitted and
imperfectly described, can provide insight into potential safety
concerns, yet they remain “after the fact” descriptors.

Many other variables, usually not described in AERs, impact the
safety of BDS, especially proprietary blends: genetics, exercise,
concomitant use with prescription and/or nonprescription medications,
others.

Botanical Dietary Supplements (BDS):
Predicting BDS Safety
l

l

l

l

What other methods are available for predicting BDS safety?
Animal studies to predict safety can be easily performed on actual
products, preferably prior to marketing.
While animal studies are not perfect, they can help identify problematic
phytochemical combinations.
In vitro methodologies can also be useful in predicting BDS safety:
l Human hepatocytes
l Sandwich assays
l “Organ on a chip”
l Artificial intelligence / machine learning
l Others?

Botanical Dietary Supplements (BDS):
Predicting BDS Safety
l

l

l

l

A tremendous body of literature documenting in vitro HDI studies indicates
that most phytochemicals can modulate drug metabolism and/or transport in
model systems (e.g., human hepatocytes, Caco2 cells, microsomes, purified
enzymes, etc.).
However, most in vitro studies use physiologically irrelevant phytochemical
concentrations or incorporate solubilizing agents (e.g., DMSO, ethanol, etc.),
oftentimes both.
Few consumers take their BDS with DMSO!

The end result is that very few in vitro results are clinically translatable.
This has caused considerable confusion regarding HDI realities and
botanical safety.

Botanical Dietary Supplements (BDS):
A Discomfiting Legacy

•
l

l

l

Despite a 25-year tenure on the U.S. market, the lay public and
medical community remain largely ignorant of many aspects of BDS.
Comments like “BDS are natural and more safe than synthetic drugs”
are common among consumers.
While “BDS are unsafe and unregulated,” are frequent refrains among
health-care professionals.

Educating the public and medical community to the facts about BDS
remains a significant challenge.

Botanical Dietary Supplements (BDS):
Items for Discussion
l

l

l

Is DSHEA’s approach to safety, in its original form, still a
reasonable expectation for Industry and for FDA?
Industry is responsible for establishing the safety of products in
their finished form. However, if there is a concern, FDA has
burden to prove there is evidence of harm. There are examples
where FDA claims a product is unsafe and companies disagree
and continue to sell the product, does this work?
Is a more aggressive application of New Dietary Ingredient (NDI)
criteria needed?

